Six firms are set to join the Nasdaq 100 Index as part of its annual reconstitution, the benchmark’s overseer said Friday.

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, the firm is refreshing its TTR market ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

An Alnylam Pharmaceuticals drug that treats nerve pain caused by an inherited protein disorder now has results from a pivotal clinical trial showing the drug also helps patients suffering the ...

Alnylam must wait a few months longer for a verdict on its potential blockbuster-in-waiting vutrisiran. The U.S. FDA has slapped a three-month delay on its review of the RNA interference (RNAi) ...

When Alnylam scored an FDA approval for its second RNAi therapy, Givlaari, late last year, some market watchers cast a wary eye on the drug's short stay in the clinic and questionable safety profile.

The age of RNA interference drugs has arrived. Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed ...